- Home
- ZURA vs WRN Comparison
ZURA vs WRN Comparison
Compare ZURA & WRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | WRN |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | Canada |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 609.2M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | ZURA | WRN |
|---|---|---|
| Price | $4.37 | $2.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $13.00 | $4.58 |
| AVG Volume (30 Days) | 627.8K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.11 |
| 52 Week High | $7.25 | $4.26 |
Technical Indicators
Market Signals| Indicator | ZURA | WRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 45.46 |
| Support Level | $3.33 | $2.64 |
| Resistance Level | $4.58 | $3.02 |
| Average True Range (ATR) | 0.36 | 0.16 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 26.33 | 19.57 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.